TY - JOUR
T1 - Protective effect of let-7 miRNA family in regulating inflammation in diabetes-associated atherosclerosis
AU - Brennan, Eoin P
AU - Wang, Bo
AU - McClelland, Aaron
AU - Mohan, Muthukumar
AU - Marai, Mariam
AU - Beuscart, Ophelie
AU - Derouiche, Sinda
AU - Gray, Stephen
AU - Pickering, Raelene
AU - Tikellis, Chris
AU - De Gaetano, Monica
AU - Barry, Mary
AU - Belton, Orina
AU - Ali-Shah, Syed Tasadaque
AU - Guiry, Patrick
AU - Jandeleit-Dahm, Karin A.M.
AU - Cooper, Mark E.
AU - Godson, Catherine
AU - Kantharidis, Phillip
PY - 2017/8/1
Y1 - 2017/8/1
N2 - The let-7 miRNA family plays a key role in modulating inflammatory responses. Vascular smooth muscle cell (SMC) proliferation and endothelial cell (EC) dysfunction are critical in the pathogenesis of atherosclerosis, including in the setting of diabetes. Here we report that let-7 levels are decreased in diabetic human carotid plaques and in a model of diabetesassociated atherosclerosis, the diabetic ApoE2/2 mouse. In vitro platelet-derived growth factor (PDGF)-and tumor necrosis factor-a (TNF-a)-induced vascular SMC and EC activation was associated with reduced let-7 miRNA expression via Lin28b, a negative regulator of let-7 biogenesis. Ectopic overexpression of let-7 in SMCs inhibited inflammatory responses including proliferation, migration, monocyte adhesion, and nuclear factor-kB activation. The therapeutic potential of restoring let-7 levels using a let-7 mimic was tested: in vitro in SMCs using an endogenous anti-inflammatory lipid (lipoxin A4), ex vivo in murine aortas, and in vivo via tail vein injection in a 24-h murine model. Furthermore, we delivered let-7 mimic to human carotid plaque ex vivo and observed significant changes to the secretome in response to let-7 therapy. Restoration of let-7 expression could provide a new target for an anti-inflammatory approach in diabetic vascular disease.
AB - The let-7 miRNA family plays a key role in modulating inflammatory responses. Vascular smooth muscle cell (SMC) proliferation and endothelial cell (EC) dysfunction are critical in the pathogenesis of atherosclerosis, including in the setting of diabetes. Here we report that let-7 levels are decreased in diabetic human carotid plaques and in a model of diabetesassociated atherosclerosis, the diabetic ApoE2/2 mouse. In vitro platelet-derived growth factor (PDGF)-and tumor necrosis factor-a (TNF-a)-induced vascular SMC and EC activation was associated with reduced let-7 miRNA expression via Lin28b, a negative regulator of let-7 biogenesis. Ectopic overexpression of let-7 in SMCs inhibited inflammatory responses including proliferation, migration, monocyte adhesion, and nuclear factor-kB activation. The therapeutic potential of restoring let-7 levels using a let-7 mimic was tested: in vitro in SMCs using an endogenous anti-inflammatory lipid (lipoxin A4), ex vivo in murine aortas, and in vivo via tail vein injection in a 24-h murine model. Furthermore, we delivered let-7 mimic to human carotid plaque ex vivo and observed significant changes to the secretome in response to let-7 therapy. Restoration of let-7 expression could provide a new target for an anti-inflammatory approach in diabetic vascular disease.
UR - http://www.scopus.com/inward/record.url?scp=85025622667&partnerID=8YFLogxK
U2 - 10.2337/db16-1405
DO - 10.2337/db16-1405
M3 - Article
AN - SCOPUS:85025622667
SN - 0012-1797
VL - 66
SP - 2266
EP - 2277
JO - Diabetes
JF - Diabetes
IS - 8
ER -